Cdc25 regulates entry into mitosis by regulating the activation of cyclin B/cdc2. In humans, at least two cdc25 isoforms have roles in controlling the G 2 /M transition. Here we show, using bacterially expressed recombinant proteins, that two cdc25B splice variants, cdc25B2 and cdc25B3, are capable of activating cyclin A/cdk2 and cyclin B/cdc2, but that mitotic hyperphosphorylation of these proteins increases their activity toward only cyclin B1/cdc2. Cdc25C has only very low activity in its unphosphorylated form, and following hyperphosphorylation it will efficiently catalyze the activation of only cyclin B/cdc2. This was reflected by the in vivo activity of the immunoprecipitated cdc25B and cdc25C from interphase and mitotic HeLa cells. The increased activity of the hyperphosphorylated cdc25s toward cyclin B1/cdc2 was in large part due to increased binding of this substrate. The substrate specificity, activities, and timing of the hyperphosphorylation of cdc25B and cdc25C during G 2 and M suggest that these two mitotic cdc25 isoforms are activated by different kinases and perform different functions during progression through G 2 into mitosis.
Cdc25 regulates entry into mitosis by regulating the activation of cyclin B/cdc2. In humans, at least two cdc25 isoforms have roles in controlling the G 2 /M transition. Here we show, using bacterially expressed recombinant proteins, that two cdc25B splice variants, cdc25B2 and cdc25B3, are capable of activating cyclin A/cdk2 and cyclin B/cdc2, but that mitotic hyperphosphorylation of these proteins increases their activity toward only cyclin B1/cdc2. Cdc25C has only very low activity in its unphosphorylated form, and following hyperphosphorylation it will efficiently catalyze the activation of only cyclin B/cdc2. This was reflected by the in vivo activity of the immunoprecipitated cdc25B and cdc25C from interphase and mitotic HeLa cells. The increased activity of the hyperphosphorylated cdc25s toward cyclin B1/cdc2 was in large part due to increased binding of this substrate. The substrate specificity, activities, and timing of the hyperphosphorylation of cdc25B and cdc25C during G 2 and M suggest that these two mitotic cdc25 isoforms are activated by different kinases and perform different functions during progression through G 2 into mitosis.
Regulation of the activity of cyclin-dependent kinases (cdks) 1 underlies cell cycle progression. Cdks are regulated by a combination of factors, including cyclin association, and phosphorylations and dephosphorylations of the cdk subunit. The final step in the activation of cyclin/cdks is catalyzed by a member of the cdc25 family of dual specificity phosphatases, which remove inhibitory phosphates from Thr 14 and Tyr 15 of cdk2 and cdc2.
The role and regulation of cdc25 phosphatase has been well defined in yeast and Xenopus egg systems, using a combination of genetics and biochemistry. In Schizosaccharomyces pombe, cdc25 is controlled at the transcriptional, translational, and post-translational levels. The mRNA and protein levels oscillate through the cell cycle, being maximal in G 2 , but the protein requires further post-translational modification in the form of phosphorylation for maximal activity (1, 2) . Xenopus cdc25 levels do not change, but its activity is also controlled by phosphorylation and dephosphorylation (3, 4) . In humans, three isoforms of cdc25 exist, cdc25A, -B, and -C. Cdc25A has a role in regulating the G 1 /S cell cycle phase transition whereas cdc25B and cdc25C regulated the G 2 /M transition (5) (6) (7) (8) (9) . The level of mRNA for each isoform changes through the cell cycle, but the protein levels of only cdc25A and cdc25B have been reported to change in a cell cycle-dependent manner (5, 7, 9) . All three cdc25s are phosphorylated in vivo, and phosphorylation has been demonstrated to regulate the activity of cdc25A and cdc25C (6, 10, 11) .
Whereas the in vivo substrates identified for the cdc25s to date are the Tyr-phosphorylated cyclin/cdks, cdc25 activity has usually been measured in vitro using a range of substrates, most of which are non-physiological e.g. p-nitrophenyl phosphate. The cdc25 phosphatases utilize this substrate very poorly (12) , and there is evidence that the cyclin subunit of the cdk complexes directly modifies the activity of cdc25 (13, 14) , a subtlety which would be lost with the artificial substrates. While different cdc25 isoforms have been demonstrated to activate a range of different cyclin/cdks (15) (16) (17) , there are no data on the relative activity of the cdc25 isoforms toward the different cyclin/cdks, nor data on how the observed phosphorylations of the different cdc25 isoforms affects their activities toward the cyclin/cdk substrates.
In this report, we provide biochemical evidence that two cdc25B splicing variants and cdc25C utilize cyclin A/cdk2 and cyclin B1/cdc2 as substrates with different efficiencies. Using bacterially expressed GST fusion proteins of cdc25B, cdc25C, and catalytic domain constructs, we demonstrate that in vitro two cdc25B splicing variants identified (18) 2 have relatively high activity toward both cyclin A/cdk2 and cyclin B1/cdc2, whereas cdc25C will activate cyclin B1/cdc2 to the same extent as the cdc25Bs only after hyperphosphorylation. The phosphorylation induced increases in activity of all the cdc25s are due to increased binding of the cyclin/cdks. Similar increases in activity were observed for the hyperphosphorylated forms of cdc25B and cdc25C immunoprecipitated from mitotic HeLa cells. Activity assays of chimeric constructs of cdc25B and cdc25C revealed that exchanging the N-terminal regulatory domains significantly modified their catalytic activities. We propose that mitotic hyperphosphorylation modifies the structure of the N-terminal regulatory domain of the cdc25s to allow better access of cyclin/cdk to the catalytic domain.
MATERIALS AND METHODS
Cell Culture and Synchrony-HeLa cells were cultured in RPMI 1640 with 5% bovine serum (Serum Supreme, Biowhittaker). Single and double thymidine block/release synchronies of HeLa cultures were performed as described previously (19) .
Production and Expression of GST-cdc25s-Production of GST fusion proteins of wild type and catalytically inactive C/S and CR/SK mutants of cdc25B3 (using the nomenclature of Baldin et al. (18) ) and cdc25C, * This work was supported in part by the National Health and Medical Research Council of Australia and the Queensland Cancer Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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where critical Cys and Arg residues have been mutated to Ser and Lys, are described elsewhere (9, 20) , and production of GST-cdc25B2 is described elsewhere. 2 The cdc25 chimeras were produced by cutting full-length cdc25B3 and cdc25C in pUCSR␣ (9) with AvrII, which cuts the vector 5Ј of the cloned cDNAs and both cdc25s in the N-terminal regulatory domains. The excised AvrII/AvrII fragments from each cdc25 were then subcloned into the corresponding sites of the other cdc25. The fragments were ligated in-frame and encoded chimeric cdc25s from cdc25B3 codon 1-251 and cdc25C 181-472 (designated cdc25BC2), and cdc25C codon 1-180 and cdc25B3 252-580 (designated cdc25CB3). The chimeras were then subcloned in pGEX 2T (Pharmacia) as either an XbaI/XbaI fragment of cdc25BC2 into the XbaI-digested pGEX-cdc25B3 (9), or BamHI/BamHI fragment of cdc25CB3 subcloned in BamHI digested pGEX 2T. The production of GST fusion proteins of the Cterminal fragments of both cdc25B3 and cdc25C has been described elsewhere (20) . 2 The GST fusion proteins were expressed in Escherichia coli DH5␣ and the induced proteins were extracted by Sarkosyl lysis and affinity purified on glutathione-agarose as described previously (9) , modified to include 5 mM DTT in all extraction and washing buffers.
Cdc25 Activity Assays-The activity of the GST-cdc25 fusion proteins was assayed by their ability to activate the Tyr 15 -phosphorylated forms of cyclin B1/cdc2 or cyclin A/cdk2. The cdc25 activity was quantitated as the increased histone H1 kinase activity of the activated cyclin/cdk. The cyclin/cdks were isolated by immunoprecipitation with either anti-cyclin B1 antibody (9) from extracts of HeLa cells harvested 8 h after release from an overnight block in 2.5 mM thymidine (when the cells are in late S or early G 2 phase, S/G 2 ), or an anti-cdk2 polyclonal (Santa Cruz) or anti-cyclin A monoclonal (Pharmingen) antibody from overnight thymidine-blocked HeLa cells (G 1 /S). The cell lysates were prepared and immunoprecipitations performed as described previously (9) . Affinity purified GST-cdc25s were eluted from glutathione-agarose with 10 mM reduced glutathione in phosphatase buffer (20 mM Tris⅐HCl, 2 mM EDTA, 5 mM DTT, 150 mM NaCl, 0.1% Triton X-100, pH 8.3) supplemented with 0.1 mg/ml bovine serum albumin. The amount of GST-cdc25 eluted was quantitated by laser densitometry of Coomassie Blue-stained bands of the full-length fusion proteins in 30-l aliquots resolved on a 10% SDS-PAGE gel (Fig. 1B) , using bovine serum albumin as a standard. The eluted GST-cdc25s (30 l) were added to immunoprecipitates of either cyclin B1/cdc2 or cyclin A/cdk2, and incubated for 20 min at 30°C. The reaction was stopped by addition of 5 l of 5 mM sodium vanadate, and the histone H1 kinase activity assayed as described previously (9) . The level of histone phosphorylation was quantitated by PhosphorImaging and the cdc25 activity expressed as fold increase in histone kinase activity over the control, normally the catalytically inactive GST-cdc25B3 CR/SK mutant. Where indicated, the eluted GST-cdc25s were diluted with elution buffer. In all assays, GST-cdc25CB3 was initially diluted 3-fold to give a similar level of protein as that of the eluted GST-cdc25Bs and GST-cdc25C.
The activity of HeLa cell cdc25B and cdc25C was assayed by immunoprecipitation from extracts of either G 1 /S or S/G 2 synchronized cells, or mitotic cells (M) obtained by mitotic shake-off of cells arrested in M phase with nocodazole (0.2 g/ml) 14 h after release from a thymidine block. Cells were lysed in NETN (20 mM Tris⅐HCl, 1 mM EDTA, 100 mM NaCl, 0.5% Nonidet P-40, pH 8) supplemented with 0.3 M NaCl, 5 mM DTT, 5 g/ml leupeptin, aprotinin, and pepstatin, and 0.5 mM phenylmethylsulfonyl fluoride, and the phosphatase inhibitors 0.1 mM sodium vanadate, 10 mM sodium fluoride, 2 M microcystin, and 20 M cantharidin. The lysates were precleared with 30 l of a 50% suspension of protein A-Sepharose for 30 min then the cdc25s were immunoprecipitated by addition of 0.1-0.5 g of either affinity purified cdc25B or cdc25C specific antibody (9) and 30 l of 50% protein A-Sepharose. The antibody was incubated with the lysate for 3 h at 4°C, then the precipitates washed as for the glutathione-agarose precipitates with NETN supplemented with 5 mM DTT. Finally, the precipitates were washed once with phosphatase buffer into fresh tubes, and the cdc25 activity assayed by the activation of a Thr 14 /Tyr 15 and Thr 161 -phosphorylated cdc2-cyclin B1 complex (PY15) produced in vitro. Briefly, baculovirusexpressed human cyclin B1 GST fusion protein was bound to glutathione-agarose, then incubated in a HeLa cell lysate with the addition of 2 mM ATP, 15 mM MgCl 2 , and the cdk inhibitor olomoucine (0.1 mM). The agarose bound GST-cyclin B1/cdc2 was washed and cleaved from the GST moiety with thrombin. The released Thr 14 , Tyr 15 , and Thr 161 -phosphorylated cdc2/cyclin B1 was then stored at Ϫ70°C until use. 5 l of PY15 substrate was diluted with 15 l of phosphatase buffer and incubated with the immunoprecipitated cdc25 for 30 min at 30°C. The reaction was stopped by addition of 5 l of 5 mM sodium vanadate, and the increase in H1 kinase activity measured as described above. Cdc25 activity was quantitated as the increased histone kinase activity of the substrate. The controls in these experiments were preimmune IgG immunoprecipitates from M phase samples, although preimmune control values from each cell cycle sample were the same.
In Vitro Phosphorylation and Dephosphorylation of Cdc25-In vitro phosphorylation of the GST-cdc25s was performed using extracts of mitotic HeLa cells obtained from mitotic shake-off of overnight nocodazole-blocked HeLa cultures. The cells were lysed in 50 mM Tris⅐HCl, 5 mM EDTA, 250 mM NaCl, 5 mM DTT, 0.1% Triton X-100 with protease and phosphatase inhibitors as above, except that the vanadate concentration was increased to 0.3 mM and microcystin to 5 M. The lysate was precleared by incubation with 0.4 ml of a 50% suspension of glutathione-agarose for 1 h, then 2-4 mg of lysate was added to GST-cdc25s bound to glutathione-agarose. The GST-cdc25s were incubated with the lysates either with or without addition of 2 mM ATP and 15 mM MgCl 2 for 15 min at 30°C, then supplemented with a further 1 mM ATP and incubated a further 15 min. The glutathione-agarose bound GST-cdc25s were then washed, eluted, and assayed as described above. In some cases, the phosphorylated cdc25s were dephosphorylated prior to elution using 1 unit of -phosphatase (New England Biolabs) for 30 min at 30°C as per the manufacturer's conditions. The degree of phosphorylation was assessed by electrophoresis of the eluted GST-cdc25s on 10% SDS-PAGE, and immunoblotting the resolved proteins with an anti-GST antibody. The phosphorylated cdc25s migrated as lower mobility species (9, 10) .
Cdc25-associated Cyclin/Cdks-Molt4 cells harvested 8 h after release from a thymidine block (predominantly S/G 2 phase cells), were lysed in NETN supplemented with 0.3 M NaCl, 5 g/ml leupeptin, pepstatin, and aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium vanadate, and 20 mM sodium fluoride, and precleared with glutathione-agarose for 1 h at 4°C. GST-cdc25 C/S mutants bound to glutathione-agarose was incubated in 1.25 mg of lysate at 0.5 mg/ml protein for 2 h at 4°C, the bead pellets washed 4 times with NETN, and the bound protein eluted by boiling in 2 ϫ SDS sample buffer. The eluted proteins were analyzed by immunoblotting with either anti-cdc2 (Santa Cruz) monoclonal antibody, anti-GST, or anti-cdk2 (Santa Cruz) affinity purified polyclonal antibodies, using ECL detection.
p-Nitrophenylphosphatase Assays-p-Nitrophenyl phosphate (30 mM) in phosphatase buffer was added to 60 l of eluted GST-cdc25 to give a final volume of 200 l, and incubated at 30°C for 1 h. The reaction was stopped by the addition of 300 l of 2 M NaOH and the turnover of p-nitrophenyl phosphate determined as the increased absorbance at 410 nm using the ⑀ of 18,000 M Ϫ1 cm Ϫ1 for p-nitrophenol.
RESULTS

Production of cdc25B and cdc25C
Chimeras-To investigate the intrinsic activities of the two splicing variants of cdc25B and cdc25C, GST fusion proteins of each were expressed in bacteria and purified by glutathione-agarose affinity chromatography. These proteins have previously been shown to be active as phosphatases in vitro, using a number of different substrates (9, 15, 20) . A series of chimeric proteins were also produced, where the conserved N-terminal regions of the cdc25B3 variant and cdc25C were exchanged (Fig. 1A) . Exchange of the N-terminal regions was expected to change the regulation and possibly substrate specificity of chimeric catalytic subunit, but not change its catalytic properties significantly. Full-length GST fusion proteins were expressed and purified for each of the cdc25s, C-terminal constructs and two chimeric proteins, but we were unable to purify a full-length version of another chimeric cdc25, cdc25BC1 (Fig. 1B) .
The activity of the GST-cdc25s was initially assayed using p-nitrophenyl phosphate as substrate. The catalytic C-terminal regions of the two cdc25Bs and cdc25C display a high degree of sequence identity and would thus be expected to have similar catalytic properties. When the activities of the GST-cdc25s were compared on an equimolar basis, cdc25B C-terminal fragment construct was found to have a 4 -5-fold greater activity than either cdc25B variant, which had similar activities with p-nitrophenyl phosphate (Table I ). The full-length cdc25C and its isolated C-terminal domain construct had similar activity with this substrate, although this was less than half the activity of the cdc25Bs. Interestingly, the two full-length chimeras had very different p-nitrophenylphosphatase activities from their parent forms, cdc25BC2 was essentially inactive with this substrate, whereas cdc25CB3 had 3-fold higher activity than cdc25B3, but a similar activity to the cdc25B C-terminal fragments (Table I) .
The activity of the GST-cdc25Bs and GST-cdc25C with pnitrophenyl phosphate indicated only small differences between the catalytic activities of the bacterially expressed proteins. Others have shown that the cyclin subunit of the in vivo substrates of cdc25, the cyclin/cdks, can contribute to the activity and possibly specificity of the cdc25 (13, 14) . To investigate this possibility, the activity of the GST-cdc25s, chimeras, and C-terminal constructs toward Thr 14 /Tyr 15 -phosphorylated cdc2/cyclin B1 isolated from S/G 2 HeLa cells and Tyr 15 -phosphorylated cdk2/cyclin A isolated from G 1 /S HeLa cells was assayed. The activity of each GST-cdc25 was assayed as a dilution series to account for the differences in the levels of each GST fusion protein expressed in bacteria, and their different relative activities. Cdc25 activity was measured by the activation of immunoprecipitated, Tyr 15 -phosphorylated cyclin/ cdk, and quantitated in terms of the increased histone kinase activity of the complexes (Fig. 2A) .
Cdc25B C-terminal fragments and chimeric cdc25CB3 had the highest relative activities toward both cyclin B1/cdc2 and cyclin A/cdk2 (Fig. 2, B and C ). Cdc25B2 and cdc25B3 had similar levels of activity toward cyclin B1/cdc2, but cdc25B2 displayed a 2-4-fold higher activity toward cyclin A/cdk2 than FIG. 1. A, schematic diagram of the GST-cdc25s and chimeras used. The restriction sites used to construct the chimeras and C-terminal domains, and the codons at which they cut are indicated. The conserved catalytic domain of cdc25B3 and cdc25C, cdc25B3[385-581] and cdc25C , are shown as differently shaded regions. B, Coomassie Blue-stained SDS-PAGE gel of eluted GST-cdc25s and chimeras used. The strongly staining bands less than 36 kDa are premature termination products of the GST fusion proteins. The minor bands migrating between these and the full-length proteins are truncations in the C-terminal catalytic domain and therefore inactive.
TABLE I p-Nitrophenylphosphatase activity of the GST-cdc25s
The activity of each GST-cdc25 was calculated from five separate experiments, and calculated as described under "Materials and Methods." cdc25B3. Neither GST-cdc25C, cdc25C C-terminal fragments, nor chimeric cdc25BC2 displayed significant activity toward cyclin A/cdk2, although GST-cdc25C and GST-cdc25C C-terminal fragments activated cyclin B1/cdc2 2-3-fold. The difference in the relative activities of the GST-cdc25s toward p-nitrophenyl phosphate and the immunoprecipitated cyclin/cdks was not a consequence of steric interference of the GST moiety, as removal of the GST moiety with thrombin followed by assay using p-nitrophenyl phosphate or immunoprecipitated cyclin B1/cdc2 gave similar relative activities (data not shown).
Mitotic Phosphorylation and Activation of the GST-Cdc25s-Mitotic hyperphosphorylation of cdc25C is associated with its increased activity using a number of non-physiological substrates (10, 11), and phosphorylation of cdc25B is correlated with its activity in vivo (9) . To test the effects of mitotic hyperphosphorylation on cdc25 activity toward cyclin A/cdk2 and cyclin B1/cdc2, the full-length GST-cdc25s and chimeras were phosphorylated in vitro using extracts from mitotic HeLa cells. The phosphorylated cdc25s displayed the characteristically retarded electrophoretic mobilities observed for these proteins in vivo ( Fig. 3A ; Refs. 9 and 10). In these experiments, all of the GST-cdc25C was shifted to the hyperphosphorylated form as was cdc25CB3, whereas only half of the cdc25B2, cdc25B3, and cdc25BC2 was in the retarded form. The phosphorylated GSTcdc25s were assayed for their activity toward immunoprecipitated S/G 2 cyclin B1/cdc2 (Fig. 3B) . Hyperphosphorylation of GST-cdc25B2 and cdc25B3 resulted in 2-3-fold and 3-5-fold activation, respectively. Chimeric GST-cdc25BC2 again showed no activity after mitotic phosphorylation, although phosphorylation of the cdc25B3 N-terminal regulatory domain produced a similar change in electrophoretic mobility to that seen in the full-length cdc25Bs (Fig. 3A) . GST-cdc25CB3 showed a small increase in activity (no more than 2-fold), whereas phosphorylation of GST-cdc25C produced the greatest increase in activity, to have greater cdc25 activity on a relative mole cdc25 basis than either of the activated cdc25Bs, although this was still less than the activated GST-cdc25CB3 (Fig. 3B,  lower panel) . The increased histone kinase activity was not due to any histone kinase associated with the phosphorylated GSTcdc25s from the HeLa extracts used for phosphorylation, as no increase in histone kinase activity was associated with mitotic phosphorylation of the catalytically inactive GST-cdc25B3 CR/SK mutant, which was used as the control for this experiment or with GST-cdc25BC2.
To determine whether the mitotic phosphorylation of the
FIG. 2. Relative activities of the GST-cdc25s.
A, the activity of each GST-cdc25 was measured using serial dilutions of the eluted proteins, with the inactive GST-cdc25B3 CR/SK mutant as a control. The GST-cdc25s were incubated with immunoprecipitated Thr 14 /Tyr 15 -phosphorylated cyclin B1/cdc2 or cyclin A/cdk2 and the increased histone H1 kinase activity was quantified as a measure of the relative cdc25 activities. The dilution series for GST-cdc25B2 is shown with the undiluted, inactive GST-cdc25B3 CR/SK mutant control. The top half of the gel was immunoblotted for cdc25B (␣cdc25B), and the cdc25 activity quantified as increased histone H1 kinase activity (H1K) of the activated cyclin B1/cdc2 immunoprecipitate on the lower half. B and C, the activity of GST-cdc25B C-terminal (solid circles), cdc25CB3 (solid squares), cdc25B2 (solid diamonds), cdc25B3 (open squares), cdc25C (solid triangles), cdc25BC2 (open diamonds), and cdc25C C-terminal (open circles) were assayed for activation of cyclin B1/cdc2 (B) and cyclin A/cdk2 (C). The amount of cdc25 in each assay is expressed as the number of moles of cdc25 relative to the number of moles of GSTcdc25B3 in the undiluted sample, which has been normalized to 1 mol. Cdc25 activity is expressed as fold increase in histone kinase activity over the control incubation with catalytically inactive GST-cdc25B3 CR/SK mutant.
FIG. 3. Hyperphosphorylation of GST-cdc25s by mitotic kinases increases their activity.
A, GST-cdc25s were incubated in mitotic HeLa cell extracts either with or without the addition of Mg/ ATP. The hyperphosphorylated forms of the GST-cdc25s are visible as the slower mobility bands detected with an anti-GST antibody (␣GST). B, the cdc25 activity of the hyperphosphorylated and unphosphorylated GST-cdc25s were measured as described in the legend for Fig. 2 GST-cdc25s was directly responsible for the increased activities observed, the GST-cdc25s were phosphorylated as in the previous experiment, then incubated either with or without recombinant -phosphatase to dephosphorylate the proteins, following which the phosphatase was washed away and the GSTcdc25s assayed for activity using immunoprecipitated S/G 2 cyclin B1/cdc2 and G 1 /S cyclin A/cdk2 as substrates. Thephosphatase completely dephosphorylated the GST-cdc25s in each case (Fig. 4A) . Interestingly, the hyperphosphorylated GST-cdc25C was poorly stained with the anti-GST antibody, which was also seen using anti-cdc25C antibody (data not shown). The differences in the activity levels of the phospho and dephospho-forms of the GST-cdc25s for cyclin B1/cdc2 (Fig.  4B) were similar to those seen with the phosphorylated and unphosphorylated GST-cdc25s in the previous experiment (Fig.  3B) . Surprisingly, the mitotic phosphorylation of the GSTcdc25s had little effect on their activity toward the immunoprecipitated cyclin A/cdk2 (Fig. 4B, lower panel) . The low degree of cdc25 activation in the experiment shown was due to the relatively high histone kinase activity of the immunoprecipitated cyclin A/cdk2. Despite this high background, GSTcdc25CB3 produced a 5-fold activation, indicating that the lack of hyperphosphorylation induced increase in activity of the GST-cdc25s similar to that seen with cyclin B1/cdc2 was not due to an insensitive cyclin A/cdk2 substrate. In this experiment, anti-cdk2 immunoprecipitates were used, but a similar lack of phosphorylation dependent activation was observed using anti-cyclin A immunoprecipitates (data not shown). The small increase in GST-cdc25B3 activity with cyclin A/cdk2 was consistently observed.
The mechanism by which the mitotic phosphorylation increased the activity of cdc25B and cdc25C was further investigated, taking advantage of the ability of the catalytically inactive cdc25 C/S mutants to form stable complexes with the substrate cdk-cyclin complexes (21) . The C/S mutants of GSTcdc25B2, cdc25B3, and cdc25C were hyperphosphorylated with mitotic HeLa extracts as in the previous experiments, and were used to pull down interacting cdk/cyclins from extracts of synchronized S/G 2 Molt4 cells. The binding of cdk2 and cdc2 complexes was analyzed by immunoblotting, compared with the unphosphorylated GST-cdc25s as controls. The levels of hyperphosphorylation obtained were equivalent to those obtained in the earlier phosphorylation experiments (Fig. 5) . GST-cdc25B2 C/S mutant bound a high level of cdk2 compared with the other GST-cdc25 C/S mutants, with no phosphorylation-dependent increase, whereas GST-cdc25B3 C/S displayed a small, 1.5-3-fold increase in cdk2 binding with phosphorylation, and GSTcdc25C C/S bound only very low levels of cdk2. By contrast, all GST-cdc25 C/S mutants displayed significant phosphorylation dependent increases in cdc2 complex binding, with cdc25B2 having a 2-4-fold increase, while GST-cdc25B3 and GSTcdc25C displayed a 5-10-fold increase in cdc2 association; the smaller phosphorylation dependent increase with GSTcdc25B2 was related to the higher levels of cdc2 bound by its unphosphorylated form (Fig. 5) .
Activity of Interphase and Mitotically Phosphorylated Cdc25s in Vivo-Measurement of the in vitro activity and activation of the GST-cdc25s provides a useful indicator of the intrinsic activities of the unmodified recombinant proteins, and the effect of mitotic phosphorylation. However, other factors apart from the phosphorylation status of these proteins may effect their activities. To test whether this was the case, the activities of the immunoprecipitated cdc25B and cdc25C from synchronized HeLa cell cultures were measured using a soluble Thr 14 / Tyr 15 -phosphorylated cdc2/cyclin B1 (PY15) produced in vitro. Immunoprecipitated cdc25B (this included both cdc25B2 and cdc25B3) was active in S/G 2 HeLa cell samples, but the mitotically phosphorylated cdc25B was further activated, in this case 2-fold (Fig. 6A) . In these experiments only half of the cdc25B was in the electrophoretically retarded form, suggesting that hyperphosphorylation of the entire complement of cdc25B would produce at least a 4-fold increase in activity. Dephosphorylation of the hyperphosphorylated form usingphosphatase resulted in the loss of the slower mobility form of the protein and reduction of its activity, although this was still higher than S/G 2 levels (Fig. 6B) . Immunoprecipitated cdc25C was found to have a very low level of activity in G 1 /S phase cell samples, and S/G 2 samples showed only a small but reproducible increase in activity, although this was much less than the activity of the mitotic samples (Fig. 6C) , which mirrored the Ͼ10-fold increased activity observed in vitro (Fig. 4B) . Dephosphorylation of the hyperphosphorylated cdc25C resulted in the loss of the retarded mobility form of the protein and reduction of cdc25C activity to G 1 /S phase levels (Fig. 6D) , as shown by others (10, 11) . This supports the model for the mitotic activation of cdc25C being through its mitotic hyperphosphorylation. However, the inability of -phosphatase to reduce cdc25B activity to S/G 2 levels, even though it did completely convert cdc25B to the more rapidly migrating form, suggests that other factors in addition to phosphorylation may be involved in the mitotic activation of cdc25B.
The different substrate specificities and enzyme activities through the cell cycle suggested that cdc25B and cdc25C may   FIG. 4 . Hyperphosphorylation of the GST-cdc25s increased their activity with cyclin B1/cdc2 but not cyclin A/cdk2. A, GSTcdc25s were hyperphosphorylated as described in the legend to Fig. 3 , and then incubated either with or without -phosphatase (). The dephosphorylation was detected as an increase in the electrophoretic mobility of the bands immunoblotted with anti-GST antibody. B, the activity of the hyperphosphorylated and dephosphorylated GST-cdc25s in A shown as histone kinase activity and quantified as fold increase over the CR/SK control, with either immunoprecipitated cyclin B1/cdc2 or cyclin A/cdk2 as substrate.
FIG. 5. Hyperphosphorylation increases the affinity for cdc2
but not cdk2-cyclin complexes. GST-cdc25 C/S mutants were hyperphosphorylated as in Fig. 3 , incubated in extracts of Molt4 cells synchronized in late S/G 2 phase, and the levels of bound cdc2 and cdk2-cyclin complexes assessed by immunoblotting for these proteins. The relative levels of GST-cdc25s are indicated in the GST immunoblot. Lysates of asynchronously growing HeLa cells were also run as controls for the immunoblotted cdc2 and cdk2. The strongly staining band running ahead of the cdk2 doublet is a cross-reactive species.
regulate the activation of different pools of mitotic cyclin/cdks. This was further supported by the timing and proportion of the cdc25B and cdc25C activated during the cell cycle. Immunoblotting of HeLa cells synchronized using a double thymidine block/release protocol, which resulted in up to 80% of cells progressing synchronously from early S phase through to mitosis, revealed hyperphosphorylated forms of cdc25B as early as 8 h after release, when cells were in late S/early G 2 phase, preceded the activation of cyclin B1/cdc2 (Fig. 7) . In contrast, the hyperphosphorylated form of cdc25C was only detected at 10 h simultaneous with the activation of cyclin B1/cdc2. The hyperphosphorylated form accounted for only a small proportion of the total cdc25C. This low proportion is clearly indicated by the apparently similar levels of the underphosphorylated cdc25C in all the time point samples, and cannot be accounted for by incomplete synchrony of the cultures, loss due to dephosphorylation in the extract as the majority of the cdc25B is present in hyperphosphorylated form at 10 h after release (Fig.  7) , or the reduced sensitivity of immunoblotting for the hyperphosphorylated form already noted with the in vitro hyperphosphorylated cdc25C (Figs. 4A and 5 ).
DISCUSSION
The in vitro analysis of cdc25 substrate specificity and activation reported here has provided a biochemical basis for the observed activities of cdc25B and cdc25C in vivo. The catalytic properties of the isolated catalytic domains of these two phosphatases were surprisingly different considering they share over 56% identity and 67% homology of the amino acid sequences in the conserved catalytic domains. The cdc25B Cterminal had the highest activity of all the GST-cdc25s with all of the substrates used, whereas cdc25C C-terminal fragments dephosphorylated p-nitrophenyl phosphate and cyclin B1/cdc2 at only 10% the rate of cdc25B C-terminal fragments and was essentially inactive with cyclin A/cdk2 (Table II) . This suggests that some of the differences in activities of the full-length cdc25s is due to the different activities of the catalytic domains. Interestingly, full-length cdc25C and its C-terminal domain construct had similar activities toward p-nitrophenyl phosphate, consistent with a previous report (20) , and the cyclin/ cdks, whereas cdc25B2 and cdc25B3 had only 25% the activity of their common catalytic domain construct with all the substrates tested here (Table II) . The difference in the catalytic activities of cdc25B2 and similar C-terminal constructs has also been observed by others using p-nitrophenyl phosphate as a substrate (21) .
The relative ability of the bacterially expressed GST-cdc25s to bind cyclin A/cdk2 and cyclin B1/cdc2 generally reflected the relative catalytic rates of the GST-cdc25s with cyclin A/cdk2 and cyclin B1/cdc2. 2 Hyperphosphorylation of the GST-cdc25s resulted in increased binding of cyclin B1/cdc2, which would FIG. 6 . In vivo activity of cdc25B and cdc25C through the cell cycle. Immunoprecipitated cdc25B and cdc25C were assayed using the soluble PY15 substrate (see "Materials and Methods"). The immunoprecipitated proteins were detected by immunoblotting, and the activity measured as the increase in histone H1 kinase activity of PY15 compared with preimmune control precipitates. A and C represent averages and standard deviation of triplicate determinations. In B and D, cdc25 immunoprecipitates from identical samples were incubated either without or with -phosphatase (ϩ), and the activities represent the mean of duplicate determinations.
FIG. 7.
Cdc25B and cdc25C are hyperphosphorylated at different times during the cell cycle. HeLa cells were synchronized in early S phase with a double thymidine block/release, and progression through the cell cycle was monitored by flow cytometric analysis of the DNA content of the cells after release from the second thymidine block. The activation of cyclin B1/cdc2 was monitored by cyclin B1 immunoprecipitate histone H1 kinase assays, and samples were immunblotted with anti-cdc25B and anti-cdc25C antibodies.
contribute to the increased catalytic rates for cyclin B1/cdc2 observed. In the case of cdc25B2 and cdc25B3, increased substrate binding could completely account for the increased activity, whereas it would appear that increased substrate binding may only partially account for the increased cdc25C activity (Table II) , the remainder perhaps due an increase in its intrinsic catalytic rate. The increased activity of the hyperphosphorylated forms of cdc25B and cdc25C immunoprecipitated from mitotic HeLa cells compared with the underphosphorylated forms from S/G 2 cells was comparable with the increase obtained with in vitro hyperphosphorylation. In the case of cdc25C, the increased activity was due solely to the effects of phosphorylation, in agreement with observations by others (10, 11) . However, the inability of -phosphatase to reduce the activity of hyperphosphorylated cdc25B to S/G 2 levels despite the apparently complete dephosphorylation of the immunoprecipitated cdc25B suggests that other modifications might also contribute to its mitotic activation in vivo.
The chimeric cdc25s have provided insight into the mechanism by which the N-terminal domains may regulate the activity of the cdc25s. The exchange of similarly sized N-terminal domains which have little sequence similarity has resulted in chimeric cdc25s with catalytic properties unlike either of the parent proteins. The lack of effect of mitotic hyperphosphorylation on the activity of chimeras compared with the parent cdc25s suggests that the chimeric N-terminal and C-terminal domains are not in productive communication. The chimeras do, however, provide evidence that the N-terminal domains regulate cdc25 activity by restricting the access of substrates to the C-terminal catalytic site. For example, GST-cdc25BC2 has essentially no activity with any substrate, including the low molecular weight p-nitrophenyl phosphate, whereas the fulllength cdc25C and the C-terminal fragment constructs are capable of utilizing this substrate, suggesting that the chimeric cdc25B3 N-terminal region reduces the access to the catalytic site in the C-terminal of the chimera, which has intrinsic pnitrophenylphosphatase activity. The opposite is the case for the cdc25CB3 chimera, which has similar activity to the cdc25B C-terminal fragment construct with all the substrates tested in this study (Table II) . This suggests that the chimeric cdc25C N-terminal region allows unimpeded access of substrates to the catalytic pocket of the cdc25B C-terminal domain, equalling the access permitted by the C-terminal cdc25B construct.
The chimeric cdc25s also confirm that the major mitotic phosphorylation sites in cdc25B3 and cdc25C are located in the chimeric N-terminal regions. Cdc25CB3 contains all of the major mitotic phosphorylation sites identified in cdc25C (22), but excludes the Ser 216 site phosphorylated by a cdc25C-associated kinase (23) , and cdc25CB3 has a similar decrease in its electrophoretic mobility as cdc25C after phosphorylation in mitotic extracts. The major mitotic sites also appear to be contained within the cdc25B3 N-terminal (1-251) region, indicated by the similar electrophoretic shifts of cdc25B3 and cdc25BC2 with mitotic phosphorylation. Thus, one role for the relatively nonconserved N-terminal domain of the cdc25s may control the access of substrates to the catalytic C-terminal domain. The way in which the mitotic phosphorylations of the N-terminal domains increase cdc25 activity toward cyclin/cdks is most likely through phosphorylation-induced alterations to the tertiary structure of the proteins. In the parent cdc25s, the phosphorylation and resultant structural changes in the N-terminal region may open up the catalytic pocket to allow freer access for the substrates. However, we cannot exclude the possibility that phosphorylation may also increase the affinity of the cdc25s for the substrates, or increase the intrinsic catalytic rate. This may be particularly relevant for cdc25C, as the cdc25C C-terminal fragment construct was essentially inactive toward the cyclin/cdk substrates, in contrast to the equivalent cdc25B construct.
The surprising result that the dramatic increases in binding and catalytic activities with cyclin B1/cdc2 induced by hyperphosphorylation of the GST-cdc25s were not reflected in the binding or activity with cyclin A/cdk2, with the exception of GST-cdc25B3, which showed small increases in both binding and activity for this complex, suggests that interaction of cyclin B1/cdc2 and cyclin A/cdk2 with the cdc25s is very different, and that the conformational changes induced by hyperphosphorylation of the N-terminal domain affects cyclin A/cdk2 access/ affinity to the catalytic site only minimally. The reason for this lack of phosphorylation-dependent effect with cyclin A/cdk2 may be due to structural differences between the cyclin A and cyclin B1-cdk complexes and the manner in which these complexes interact with the cdc25s. The cdks have a high degree of sequence identity, whereas, outside a few conserved domains, cyclins are quite divergent and are likely to possess very different tertiary structures. Structural differences are also suggested by the range of binding affinities of the cdk inhibitor proteins, e.g. p21CIP1 and p27Kip1, for cyclin A and cyclin B-cdk complexes (24) .
Cell cycle analysis of expression of cdc25B and cdc25C shows the expected dramatic increase in cdc25B proteins (cdc25B3 is the most abundant form, although cdc25B2 expression is also increased in G 2 ) 2 as cells enter G 2 . Interestingly, the hyperphosphorylated forms of cdc25B start to appear at 8 h after release from the thymidine block, prior to the activation of cyclin B1/cdc2. The appearance of the hyperphosphorylated cdc25C coincides with the activation of cyclin B1/cdc2 as has been reported for cdc25 in yeast and Xenopus (2-4), and supports the autoamplification model for cdc25C activation by cyclin B1/cdc2 (10) . The low proportion of cdc25C in the hyperphosphorylated form in cells transiting mitosis suggests that either the hyperphosphorylated form is a very transient species, or that only a small proportion of cdc25C is required in its activated form in mitosis. It is at present unclear as to which of these possibilities represents the true physiological situation, although the hyperphosphorylation of the total pool of cdc25C has only been found in cells blocked in mitosis with nocodazole (8) .
The specificity and timing of activation of cdc25B and cdc25C has interesting implications for their function in vivo. The abrupt increase in cdc25B levels in G 2 occurs prior to the activation of a peak of cyclin A/cdk2 in that phase of the cell cycle (25) . At this time, cdc25B2 and cdc25B3 are localized to the nucleus where the cyclin A/cdk2 is also localized (25) , and 
of GST-cdc25s towards different substrates
Relative activity of the GST-cdc25s is expressed relative to the activity of GST-cdc25C. The activity of each GST-cdc25 with cyclin A/cdk2 and cyclin B1/cdc2 is the activity at 1 mol cdc25 from Fig. 2B . Fold activation refers to the fold increase in activity with cyclin B1/cdc2 at 1 mol of each hyperphosphorylated GST-cdc25 from Fig. 3B . Cdc2 binding refers to the fold increase in cdc2 associated with the hyperphosphorylated GST-cdc25 C/S mutants in Fig. 4 the in vitro substrate specificity experiments indicate that cyclin A/cdk2 is a good substrate for both cdc25Bs. Thus cdc25B2 and cdc25B3 may first activate cyclin A/cdk2 in G 2 , then cdc25B3 accumulates in the cytoplasm where it activates part of the pool of cyclin B1/cdc2, which in turn catalyzes changes in microtubule dynamics and increased levels of microtubule nucleation at the centrosome, both of which are blocked by overexpressing catalytically inactive mutants of cdc25B3 (9) . The translocation of cyclin B1/cdc2 from the cytoplasm to the nucleus in prophase is correlated with the conversion of the centrosomes to mitotic microtubule organizing centers (26) , and thus translocation of cyclin B1/cdc2 must occur after cdc25B3 appears in the cytoplasm. It is unclear as to what proportion of the cyclin B1/cdc2 pool is active when it is translocated, but cdc25C may be hyperphosphorylated by the active cyclin B1/ cdc2 translocated into the nucleus, and the former may in turn activate the remainder of the translocated pool of cyclin B1/ cdc2. The hyperphosphorylated cdc25C may also act on other, unidentified substrates, but appears not have a role in the activation cyclin A/cdk2. In summary, we have shown that recombinant cdc25B2 and cdc25B3 have relatively high activity toward Tyr
15
-phosphorylated cdc2/cyclin B1 and cdk2/cyclin A, with cdc25B2 having a higher activity with cdk2/cyclin A than cdc25B3. Cdc25C possesses only very low or no activity with these substrates in vitro. The hyperphosphorylated forms of these proteins all showed increased activity with cdc2/cyclin B1, but little increase in activity with cdk2/cyclin A. This was reflected in the relative binding efficiencies of the cdc25s for the cdk-cyclin complexes. Similar phosphorylation-dependent increases in cdc25 activity where observed for cdc25B and cdc25C in vivo. These data indicate that the different cdc25s potentially regulate different pools of cdk/cyclins, and suggest that the phosphorylation dependent activation of the cdc25s is due to conformational changes which result in increased access to the catalytic pocket for the substrates.
